BioNTech, Pfizer begin German part of coronavirus vaccine study


FRANKFURT (Reuters) - Biotech firm BioNTech said on Monday it widened an ongoing pivotal global study of its COVID-19 vaccine candidate to include testing in its home country of Germany. Germany's vaccines regulator, the Paul Ehrlich Institute, gave the approval for the Phase 2/3 trial of the experimental vaccine known as BNT162b2, BioNTech and its partner Pfizer said in a statement.

The global trial was initiated in July, with a view to including about 120 sites globally and seeking up to 30,000 participants in total. More.

This article is no longer available in our repository.

There could be multiple reasons for this.